Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma

Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity

“…Our previous research indicated that 4% HePC addition to the current liposomal preparation produced severe side effects in animal model (Teymouri et al, 2015). Therefore, only 2% HePC was applied in liposomal preparation.…”

“…Two percent mole ratio of HePC was incorporated in liposomal composition of Dox as the optimum therapeutic level of HePC in high cholesterol pegylated liposomal Dox (PLD) since more percent incorporation was shown to bring about severe side effects and death in our previous report (Teymouri et al, 2015). However, for Doxfree liposomal preparation 12% of HePC was applied in liposomes.…”

“…HePC introduction into liposome has displayed reduced side effect enabling their intravenous administration, although it concomitantly has reduced antitumor activity (Fichtner et al, 1994). Even in combination to Dox, HePC has not been so potential in eliminating cancerous cells in vivo (Teymouri et al, 2015).…”

Biological and pharmacological evaluation of dimethoxycurcumin: A metabolically stable curcumin analogue with a promising therapeutic potential

“…Dox nanoparticulation like Doxil is putatively known to improve anti‐tumor and chemotherapeutic features as it causes prolonged Dox accumulation in tumor, while evading heart tissues form the side‐effects of Dox (Barenholz, ; Teymouri et al, ). These nanoparticles have become successful in improving cancer therapy‐related outcome and it might be more promising if these nanoformulations will be applied together with the DiMC‐micelle (Liu et al, ; Teymouri et al, ). As previously stated, DiMC could exert cytoprotective effect in normal cells such as hepatocytes and myocardial cells (Jeong et al, ; Miltonprabu & Muthumani, ), while it could induce anticancer effect due to its pro‐oxidant property (Kunwar et al, ).…”

Biophysical Characterization of cubosomal nanoparticles intended for drug delivery applications and its interaction with a model drug: the miltefosine case

“…On the other hand, when MILT is loaded into other nanostructures, morphology alterations due to the drug incorporation may happen. In one hand, when loading MILT into liposomes, Teymouri et al (TEYMOURI et al, 2015) found that the drug did not changed significantly the morphology of the nanoparticles up to 4% w/w drug encapsulation, particle size and polydispersion remained the same with and without the drug. In addition, when loaded into lipid nanocapsules, Eissa et al (EISSA et al, 2015) found that MILT also did not altered the colloidal properties of the lipid nanocapsules when incorporated between 25 to 100 µM, keeping the same size and polydispersion.…”